← Back to patent-cliff list
Danvatirsen
Tier C — Watch / tradeDanvatirsen
Ionis Pharmaceuticals Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Nucleic acid drug
Type
Targets：STAT3
Indications (approved)：三阴性乳腺癌, 错配修复基因缺陷型肿瘤, Non-small cell lung cancer, Lung cancer, Colorectal cancer, Pancreatic cancer, Head and neck squamous cell carcinoma, 腹水
Regional status
US
Phase II
2015-04-03
EU
Phase II
2018-12-21
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Danvatirsen?
Approved indications include: 三阴性乳腺癌, 错配修复基因缺陷型肿瘤, Non-small cell lung cancer, Lung cancer, Colorectal cancer, Pancreatic cancer, Head and neck squamous cell carcinoma, 腹水.
When does the Danvatirsen patent expire?
No public expiry year is available for Danvatirsen yet; this page updates once verified.
How do I get a quote for Danvatirsen intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-11